NCT06180005 Incidence and Characterization of Drivers Oncogenes in the Population With Lung Cancer Afferents to the Cancer Institute in Aviano (IN.ON.D.)
| NCT ID | NCT06180005 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centro di Riferimento Oncologico - Aviano |
| Condition | Non Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2024-01-06 |
| Primary Completion | 2039-01-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2024-01-06 with a primary completion date of 2039-01-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
According to an analysis by Memorial Sloan Kettering Cancer Center patients who receive a target therapy having an oncogenic driver mutation live longer than those who do not receive it. In addition to that, therapies guided by analysis on mutations identified in ct-DNA had a favorable impact, allowing longer survival. All this suggests that the presence of a therapeutically targetable oncogene (oncogene addicted) allows target therapy, resulting in a longer life expectancy. The main objective of this study is to evaluate the frequency of patients with oncogene addiction in a consecutive series of patients with NSCLC afferent to the CRO. Oncogene addiction is defined as being carriers of one of the mutations among EGFR, ALK, RET, KRAS, BRAF, Her2, ROS1, MET or other mutations that become therapeutic targets under investigation.
Eligibility Criteria
Inclusion Criteria: * First visit or first admission to CRO occurred in the period from September 2023 to September 2028 * Diagnosis of NSCLC any stage Exclusion Criteria: \- Diagnosis of tumor not of certain lung origin (uncertain origin)
Contact & Investigator
Alessandro Del Conte, MD
PRINCIPAL INVESTIGATOR
Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
Frequently Asked Questions
Who can join the NCT06180005 clinical trial?
This trial is open to participants of all sexes, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06180005 currently recruiting?
Yes, NCT06180005 is actively recruiting participants. Contact the research team at alessandro.delconte@cro.it for enrollment information.
Where is the NCT06180005 trial being conducted?
This trial is being conducted at Aviano, Italy.
Who is sponsoring the NCT06180005 clinical trial?
NCT06180005 is sponsored by Centro di Riferimento Oncologico - Aviano. The principal investigator is Alessandro Del Conte, MD at Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS. The trial plans to enroll 700 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.